findings on VEGF and PD-ECGF expression in an expanded series of 223 cases of NSCLC including T3 and N2 tumours. In particular the study evaluates the impact of the co-expression of these factors on angiogenesis and overall survival.
MATERIALS AND METHODS

Angiogenesis assessment
The JC70 monoclonal antibody (Dako) recognizing CD31 (platelet/endothelial cell adhesion molecule; PECAM-1) was used for microvessel staining on 5-µm paraffin-embedded tissue sections using the alkaline phosphatase/anti-alkaline phosphatase (APAAP) procedure as previously described (Giatromanolaki et al, 1996) . Microvessel counting was used for angiogenesis assessment. The areas of the highest vascularization were chosen at low power (×100) and microvessel counting performed on three chosen ×250 fields to establish the highest density within the tumour. The microvessel score was the sum of the vessel counts obtained in these three fields. Microvessels adjacent to normal lung were excluded from the appraisal. Vessels with a clearly defined lumen or well defined linear vessel shape, but no single endothelial cells, were counted. Microvessel scores ≥ 75 defined high vascular grade disease, and < 75, low vascular grade tumours. This cut-off point was based on a previous study where microvessel scores of 75 or higher defined a group of cases with the highest death rate as compared with other cut-off points .
VEGF immunohistochemistry
VEGF immunoreactivity was evaluated employing the VG1 monoclonal antibody and the horseradish peroxidase technique as previously described Turley et al, 1998) . The VG1 monoclonal antibody, which recognizes the 121, 165 and 189 isoforms of VEGF, was raised using recombinant VEGF 189 protein and the specificity of the antibody was confirmed using COS cells transfected with cDNA coding for VEGF 121, 165 and 189 protein and by Western blot studies. Sections were dewaxed and incubated in 0.5% hydrogen peroxide (H 2 O 2 ) in methanol for 30 min. After microwaving and washing in phosphate-buffered saline (PBS), sections were incubated with the primary antibody for 60 min. After washing in PBS for 5 min, sections were incubated with goat anti-mouse immunoglobulin (1:2000) for 30 min (Dako, UK), washed again with PBS for 5 min and incubated with rabbit anti-goat immunoglobulin (1:100) for 30 min. The peroxidase reaction was developed using diaminobenzidine (Sigma Fast tablets) as chromogen and sections were counterstained with haematoxylin. Normal rabbit immunoglobulin-G was substituted for primary antibody as the negative control (same concentration as the test antibody). Taking into account the extent of positive staining, we divided our cases into two categories: low reactivity (0-70% positive cells) and high immunoreactivity (> 70% positive cells).
PD-ECGF immunoreactivity
PD-ECGF expression in NSCLC tissue sections was assessed with the P-GF.44C monoclonal antibody as previously described (Giatromanolaki et al, 1997; Koukourakis et al, 1998) . Staining was performed using the streptavidin-biotin-peroxidase (Dako, UK) technique. Sections were dewaxed and incubated in 0.5% H 2 O 2 in methanol for 30 min. After washing in Tris-buffered saline (TBS), sections were incubated in normal human serum (1:10) for 20 min. Sections were then washed with TBS for 5 min and incubated with the undiluted primary antibody for 30 min. After washing in TBS for 5 min, sections were incubated with biotinylated goat anti-mouse immunoglobulin (1:200) for 30 min (Dako, UK). After incubation with the streptavidin-biotin complex-horseradish peroxidase (Dako, UK) for 30 min, the peroxidase reaction was developed using diaminobenzidine (Sigma Fast tablets) as chromogen, and sections were counterstained with haematoxylin. Normal rabbit immunoglobulin-G was substituted for primary antibody as the negative control. Alveolar macrophages were used as a positive internal control (Giatromanolaki et al, 1997) .
Tumour cell component was assessed for PD-ECGF expression by the intensity and extent of staining ( Figure 1D ). Two staining patterns of PD-ECGF immunoreactivity were considered: low reactivity (< 50% of cancer cells stained or diffuse weak reactivity) and high reactivity (strong staining in > 50% cells).
Intra-and interobserver variability
In previous reports we have demonstrated that intraobserver variability was minimal for vascular grade and PD-ECGF with the second assessment correlating with the first for all observers (r = 0.91, P < 0.006 and r = 0.96, P < 0.001 respectively). Similarly the interobserver variability of three investigators was low (r = 0.94, P < 0.001 for vascular grade and r = 0.91, P < 0.008 for PD-ECGF) . We made a similar observation for interobserver variability for VEGF (r > 0.93, P < 0.0001) . Therefore intra-and interobserver variability were not formally assessed in this study.
Statistics
Statistical analysis and graphic presentation were performed using the Stata 3.1 (Stata Corporation, Texas, USA) and the GraphPad Prism 2.01 package. The unpaired two-tailed t-test or Fisher's exact test was employed to test for relationships between categorical tumour variables as appropriate. Linear regression analysis was used to assess correlation between continuous variables. Survival curves were plotted using the method of Kaplan-Meier, and the log-rank test was used to determine statistical differences between life tables. A Cox proportional hazard model was used to assess the effects of patient and tumour variables on overall survival. A P-value < 0.05 was considered significant.
RESULTS
Of the 223 tumours studied 156 were squamous cell carcinomas and 67 adenocarcinomas. Forty-three patients had stage 1a, 77 stage 1b, 22 stage IIa, 52 stage IIb and 29 stage IIIa NSCLC tumours. Survival data was available for 183 patients, patients dying within 60 days of surgery being excluded to avoid bias from peri-operative death. The median follow-up at the time of analysis for patients alive was 3.5 years (range 1.5-7 years).
Vascular grade, VEGF and PD-ECGF
Eighty-nine of the 223 tumours (39.9%) were of high vascular grade. High microvessel counts were associated with advanced T-stage (P = 0.007) and node-positive (P = 0.0005) disease (Table 1) .
VEGF positive (high immunoreactivity) tumours accounted for 104/223 (46.6%) cases examined and were associated with high vascular grade disease (P = 0.009) ( Table 1) . High PD-ECGF tumour cell immunoreactivity was seen in 72/223 (32.3%) cases and likewise correlated with angiogenesis (P = 0.05) ( Table 1) . There was a weak positive correlation between VEGF and PD-ECGF expression (r = 0.21, P = 0.002).
Eighteen of the 41 (44%) NSCLC tumours with high VEGF and PD-ECGF immunoreactivity had high vascular grade disease. This was equivalent to the proportion of VEGF only and PD-ECGF only positive tumours associated with high microvessel counts (31/63; 49% and 16/31; 48% respectively). As compared to angiogenic growth factor negative disease, positive tumours were strongly associated with high vascular grade (20/88: 22.7% vs 65/135: 48.1%; P = 0.001).
Although overall no association was found between VEGF and/or PD-ECGF expression and stage of disease, high PD-ECGF expression was seen more frequently in stage 1b as compared to stage 1a NSCLC tumours (P = 0.02).
Survival analyses
Univariate analysis of survival showed that T-stage (T2 vs T1; P = 0.01: T3 vs T2 and T1; P = 0.0001), N-stage (N2 vs N1; P = 0.02: N2 vs N0; P = 0.0001: N1 vs N0; P = 0.002) and vascular grade (high vs low; P = 0.0001) were the most significant prognostic variables (Table 2) ( Figure 1A ). Both high tumour cell VEGF and PD-ECGF immunoreactivity were of prognostic significance (P = 0.02) ( Table 2 subgroup of patients beyond that seen with VEGF or PD-ECGF alone ( Figure 1D ). T-stage (P < 0.02) and vascular grade (P < 0.04) were independent predictors of outcome on multivariate analysis when all parameters were considered (Table 3a) . When analysed as a single variable, the presence of an angiogenic growth factor vs negative tumours approached significance in a multivariate model (P = 0.054) (Table 3b) . Although the numbers were relatively small the study included sufficient patients to analyse the impact of VEGF and PD-ECGF, and microvessel density on outcome in stage Ia to IIb disease (stage Ia, 37; stage Ib, 67; stage IIa, 19; and stage IIb, 44 patients). High vascular grade was associated with a poor prognosis in the stage IIb disease subgroup only (P = 0.0005). Over-expression of either or both of the angiogenic growth factors analysed was also associated with a poor outcome in stage IIb disease as compared to VEGF and PD-ECGF negative NSCLC (P = 0.02).
No association was found between histology and tumour grade and any of the parameters evaluated.
DISCUSSION
The results support the findings of previous studies indicating that the intensity of intratumoural angiogenesis, as assessed by tumour microvessel counts, has prognostic significance and plays an important role in the pathogenesis of NSCLC (Giatromanolaki et al, 1996; Fontanini et al, 1997) . This is in keeping with observations in other solid tumours including breast , colorectal (Amaya et al, 1997) and gastric cancer (Maeda et al, 1996; Takahashi et al, 1998) .
It is important to note, however, that not all studies have found a positive association between microvessel density and prognosis (Apolinario et al, 1997; Chandrachud et al, 1997; Pezzella et al, 1997) . Indeed in the largest of these studies tumours with an alveolar pattern, with no parenchymal destruction and the alveolar septae still present, had a worse outcome than those tumours with an angiogenic pattern. This observation indicates that if an appropriate blood supply is available, an NSCLC tumour may exploit it and grow within the lung without the need for neovascularization (Pezzella et al, 1997) . The study was in stage I NSCLC only. This may, to some extent, account for the lack of an association between angiogenesis and outcome as high microvessel counts are strongly correlated with tumour size and nodal status as shown in the present study and our earlier work (Giatromanolaki et al, 1996) . Finally, although there is intense debate on the subject , a recent study in lung tumours has shown considerable heterogeneity of vasculature in NSCLC specimens even within blocks from the same region of the tumour. Furthermore the periphery of the tumour, traditionally the area where blood vessels are counted, does not always contain the highest number of vessels (Schor et al, 1998) .
A number of studies have demonstrated that VEGF expression is associated with angiogenesis and/or has prognostic significance in solid tumours including breast , colorectal (Amaya et al, 1997) , gastic (Maeda et al, 1997; Takahashi et al, 1998) and pancreatic cancer (Ikeda et al, 1999) . The results of the present work confirm previous findings of an important role for tumour cell VEGF expression in the angiogenic process of, and as a prognostic factor for, NSCLC (Volm et al, 1996; Giatromanolaki et al, 1998) . VEGF overexpression was not associated with a particular stage of disease or with a negative outcome in any given disease stage subgroup (stage Ia to IIb). However, when all 183 patients were taken into consideration, univariate analysis revealed high VEGF immunoreactivity to be associated with a poor prognosis (P = 0.02). The VG1 monoclonal antibody employed in the current study detects the VEGF 121, 165 and 189 isoforms . The non-heparin binding VEGF 121 and the basic, heparin binding VEGF 165 are freely secreted from producing cells whilst the longer isoforms VEGF 189 and 206 are generally cell associated. Employing reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization techniques, VEGF 121, VEGF 165 and VEGF 189 have been found to be associated with angiogenesis and/or a poor prognosis in NSCLC (Oshika et al, 1998; Fontanini et al, 1999) .
The present study confirms our earlier work demonstrating that high PD-ECGF overexpression has a weak association with angiogenesis and prognosis, the latter on univariate analysis only. The findings are in keeping with the results of studies in malignant disease where PD-ECGF overexpression has been seen in a proportion of all solid tumours studied to date including breast (Toi et al, 1995) , colorectal (Amaya et al, 1997) , gastric (Maeda et al, 1997; Takahashi et al, 1998) , oesophageal (Igarashi et al, 1998) and pancreatic (Ikeda et al, 1999) cancers. In general, PD-ECGF is associated with angiogenesis and/or advanced disease. Furthermore overexpression may predict for poor survival (Takebayashi et al, 1996; Ikeda et al, 1999) . However, PD-ECGF immunoreactivity, be it in the malignant, inflammatory and/or stromal cells of the tumour, is not always associated with a poor outcome emphasizing the relatively weak prognostic power of this marker (Toi et al, 1995; Igarashi et al, 1998) . We observed a weak positive correlation between tumour VEGF and PD-ECGF expression (r = 0.21; P = 0.002). Similar observations have been made in colorectal cancer (Amaya et al, 1997) .
Although not seen in our study synergy between VEGF and PD-ECGF in determining the intensity of angiogenesis has been reported for breast, gastric and pancreatic cancer (Toi et al, 1995; Maeda et al, 1997; Ikeda et al, 1999) . A correlation between tumour cell VEGF and PD-ECGF-positive CD68 infiltrating inflammatory cells has been observed in gastric cancer, the vessel count being significantly higher in tumours expressing both growth factors as compared to those expressing each growth factor alone (Takayashi et al, 1998) . Furthermore, a significant association between co-expression of both angiogenic factors with the presence of hepatic metastases has been described in this disease (Maeda et al, 1997) . We found that high immunoreactivity of either or both of the angiogenic growth factors analysed conferred a poor prognosis in stage IIb disease (P = 0.02). This may reflect the contribution of these growth factors to the angiogenic process which itself is associated with a particularly poor outcome in the stage IIb patients studied (P = 0.0005).
These findings indicate that VEGF may be a suitable target for novel therapies in the management of NSCLC. Inhibition of VEGF activity with monoclonal antibodies (Kim et al, 1993) , soluble VEGF receptors (Lin et al, 1998) and VEGF-receptor 2 (Flk-1/KDR) monoclonal antibodies (Skobe et al, 1997) has shown promise in experimental in vivo models with inhibition of angiogenesis, tumour growth and/or tumour cell invasion being recorded.
As outlined earlier PD-ECGF is thymidine phosphorylase (TP), an important enzyme in the activation of 5-fluorouracil (5-FU) to fluorodeoxyuridine. TP also plays a role in converting 5-FU prodrugs, including 5′-deoxy-5-fluorouridine and the novel oral fluoropyrimidine carbamate, capecitabine, to their active metabolites (Patterson et al, 1995; Budman et al, 1998) . A recent report by our group demonstrated that there was a significant improvement in both relapse-free and overall survival in PD-ECGF/TP-positive as compared with PD-ECGF/TP-negative breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and 5-FU (CMF) chemotherapy. This was felt to be due not only to the activation of 5-FU but to the enhancement of the effectiveness of methotrexate by TP . Given the overexpression of PD-ECGF/TP seen in NSCLC, the combination of fluoropyrimidines with the more widely used cytotoxics, such as the platinums, taxanes, vinca alkaloids and topoisomerase I inhibitors, gemcitabine and ifosphamide, in the treatment of NSCLC should be evaluated further (van Zandwijk and Giaccone, 1996) .
In the present study we have clearly demonstrated that a proportion of high vascular grade tumours do not express either VEGF or PD-ECGF indicating the importance of other angiogenic factors in this regard. Apart from the more established angiogenic growth factors such as VEGF and PD-ECGF recent evidence has suggested a role for tissue factor (TF) (Koomagi and Volm, 1998) , heparin-binding growth-associated molecule (HB-GAM) (Jager et al, 1997) and CXC chemokines (Arenberg et al, 1997) in the induction of angiogenesis in NSCLC. As such other novel antiangiogenic agents, including angiostatin, endostatin, TNP-470, thalidomide and the matrix metalloproteinase inhibitors (MMPIs) may have a role to play in the treatment of NSCLC (Harris, 1998; Macaulay et al, 1999) .
In conclusion, VEGF and PD-ECGF are important angiogenic growth factors in NSCLC. The detection of a subset of high vascular grade tumours not dependent on either VEGF or PD-ECGF indicates that other angiogenic growth factors, such as bFGF, HB-GAM and TF, may have an important role in the pathogenesis of NSCLC.
